Sanofi announced that the U.S. Food and Drug Administration has approved its biologic Tzield (teplizumab‑mzwv) for use in children as young as one year old to delay the onset of stage 3 type 1 diabetes. The approval expands the drug’s existing indication, which previously covered patients eight years and older, to a younger population with stage 2 type 1 diabetes. Tzield is already approved in the EU, UK, China, Canada, Israel, Saudi Arabia, UAE, Kuwait and Brazil for adults and children aged eight and older, making this the first disease‑modifying therapy for the 1‑year‑to‑8‑year age group in the United States.
The approval was based on the PETITE‑T1D phase IV study, a single‑arm, open‑label trial that enrolled 23 children under eight years old with stage 2 type 1 diabetes. The 14‑day intravenous infusion regimen was well tolerated, with no new safety signals. Interim analysis showed that only 2 of the 23 participants progressed to stage 3, yielding an estimated non‑progression probability of 89.6%. The mean age of participants was 4.8 years, underscoring the drug’s relevance to the newly approved age cohort.
The pediatric type 1 diabetes therapeutic market was valued at USD 8.92 billion in 2023 and is projected to grow at a CAGR of 13.9% from 2024 to 2030. By adding the 1‑year‑to‑8‑year segment, Sanofi now has access to a larger addressable market, potentially increasing future sales of Tzield and reinforcing its position in the growing early‑intervention space.
Tzield’s approval positions Sanofi as the first company to offer a disease‑modifying therapy for children with stage 2 type 1 diabetes. Early intervention can preserve beta‑cell function and delay the need for insulin therapy, aligning with Sanofi’s broader strategy of targeting the immune system early in autoimmune diseases. The move strengthens Sanofi’s competitive stance in a market where timing of treatment is critical and where no other product currently offers a similar mechanism of action for this age group.
Sanofi’s recent financial performance reflects a company that is successfully leveraging its pipeline. Q1 2025 earnings reported sales of €9.9 billion and an adjusted EPS of €1.79, while Q4 2025 sales rose to €11.3 billion with a 26.7% EPS growth. The company projects Q1 2026 revenue of €10.23 billion and an EPS of €1.8. The new indication for Tzield is expected to contribute to these growth trends by expanding the drug’s market reach and supporting Sanofi’s long‑term revenue trajectory.
"This approval underscores the importance of targeting the immune system early in autoimmune type 1 diabetes, aiming to impact its natural progression by delaying the loss of insulin production in the pancreas," said Christopher Corsico, Global Head of Development at Sanofi.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.